系统性治疗 – Medxy AI

Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: Key Recommendations from the ASCO Living Guideline (Version 2026.1.4)

By MedXY 08/14/2026

A clear, practice-focused summary of the 2026 ASCO living guideline on systemic treatment of metastatic castration‑resistant prostate cancer, emphasizing biomarker-driven choices, sequencing, and new options such as 177Lu‑PSMA and PARP inhibitors.

Hematology-Oncology news

Early Software-Assisted Evaluation Enhances Prediction of Survival in Newly Diagnosed Chronic Graft-versus-Host Disease Patients

By MedXY 07/13/2026

Software-assisted response evaluation at six months reliably predicts survival outcomes in chronic graft-versus-host disease, offering a promising tool to guide treatment decisions and improve patient prognosis.

Gastroenterology news Oncology

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line

By MedXY 06/28/2026

This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional CUSE framework to optimize patient outcomes beyond second-line treatment.

news Oncology

The Oncology Care Model and Starting Systemic Therapy for Cancer

By MedXY 06/10/2026

A Medicare-based study found the Oncology Care Model did not increase systemic therapy starts for newly diagnosed cancer and was linked to less treatment initiation and lower spending in poor-prognosis cancer.

news Oncology Public Health

Medicare’s Oncology Care Model Did Not Increase Systemic Therapy Starts and Was Linked to Lower Use in Poor-Prognosis Cancer

By MedXY 05/05/2026

A matched difference-in-differences study found that the Oncology Care Model did not increase systemic therapy initiation overall and was associated with lower treatment initiation and lower spending in poor-prognosis cancers.